<DOC>
	<DOCNO>NCT02954640</DOCNO>
	<brief_summary>In order accelerate identification gene responsibles PID , improve diagnosis PID , research team would like validate rapid target method high-throughput sequencing , 301 gene , know involved PID .</brief_summary>
	<brief_title>Evaluation Efficacy Sequencing Method Gene-panel</brief_title>
	<detailed_description>The Primary Immuno-Deficiencies ( PID ) set rare disease ( estimate incidence 1/5000 ) . Today , 320 PID describe , 301 , genetic cause identify , underline huge diversity PID . The genetic diagnosis PID important comprehension PID physiopathology , treatment genetic patient information . The characterisation clinical immunological phenotype patient allow identify know morbid gene 30 % case , patient , genetic cause remain unknown , due , inter alia , lack efficient tool genetic exploration . In context , year , around 600 French foreign patient explore Necker hospital CEDI ( Center Immuno-Deficiencies Explorations ) , identify , 30 % case , know genetic cause . Their treatment diagnosis patient slow , partially study dependant research funding . In addition , current practice , investigator sometimes discover incidental finding via non-targeted high throughput genetic analyzes . The aim gene-panel improve diagnosis procedure know disease , generalize rapid target method sequencing , 301 gene , know involved PID .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>Patient need genetic diagnosis PID do Necker 's CEDI ( Center ImmunoDeficiencies Explorations ) , frame initial causal mutation identification Patient sign informed consent form ( parent minor patient ) Patient affiliate National Health Care Insurance Patient refuse participate Patient legal guardianship Patient ca n't fulfill study requirement , geographic , social psychic reason</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>